Cargando…

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

BACKGROUND: Magnetic resonance imaging (MRI) has been proposed to guide breast cancer surgery by measuring residual tumour after neoadjuvant chemotherapy. This study-level meta-analysis examines MRI's agreement with pathology, compares MRI with alternative tests and investigates consistency bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinovich, M L, Macaskill, P, Irwig, L, Sardanelli, F, von Minckwitz, G, Mamounas, E, Brennan, M, Ciatto, S, Houssami, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776985/
https://www.ncbi.nlm.nih.gov/pubmed/23963140
http://dx.doi.org/10.1038/bjc.2013.473
_version_ 1782284920012406784
author Marinovich, M L
Macaskill, P
Irwig, L
Sardanelli, F
von Minckwitz, G
Mamounas, E
Brennan, M
Ciatto, S
Houssami, N
author_facet Marinovich, M L
Macaskill, P
Irwig, L
Sardanelli, F
von Minckwitz, G
Mamounas, E
Brennan, M
Ciatto, S
Houssami, N
author_sort Marinovich, M L
collection PubMed
description BACKGROUND: Magnetic resonance imaging (MRI) has been proposed to guide breast cancer surgery by measuring residual tumour after neoadjuvant chemotherapy. This study-level meta-analysis examines MRI's agreement with pathology, compares MRI with alternative tests and investigates consistency between different measures of agreement. METHODS: A systematic literature search was undertaken. Mean differences (MDs) in tumour size between MRI or comparator tests and pathology were pooled by assuming a fixed effect. Limits of agreement (LOA) were estimated from a pooled variance by assuming equal variance of the differences across studies. RESULTS: Data were extracted from 19 studies (958 patients). The pooled MD between MRI and pathology from six studies was 0.1 cm (95% LOA: −4.2 to 4.4 cm). Similar overestimation for MRI (MD: 0.1 cm) and ultrasound (US) (MD: 0.1 cm) was observed, with comparable LOA (two studies). Overestimation was lower for MRI (MD: 0.1 cm) than mammography (MD: 0.4 cm; two studies). Overestimation by MRI (MD: 0.1 cm) was smaller than underestimation by clinical examination (MD: −0.3 cm). The LOA for mammography and clinical examination were wider than that for MRI. Percentage agreement between MRI and pathology was greater than that of comparator tests (six studies). The range of Pearson's/Spearman's correlations was wide (0.21–0.92; 16 studies). Inconsistencies between MDs, percentage agreement and correlations were common. CONCLUSION: Magnetic resonance imaging appears to slightly overestimate pathologic size, but measurement errors may be large enough to be clinically significant. Comparable performance by US was observed, but agreement with pathology was poorer for mammography and clinical examination. Percentage agreement can provide supplementary information to MDs and LOA, but Pearson's/Spearman's correlation does not provide evidence of agreement and should be avoided. Further comparisons of MRI and other tests using the recommended methods are warranted.
format Online
Article
Text
id pubmed-3776985
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-37769852014-09-17 Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy Marinovich, M L Macaskill, P Irwig, L Sardanelli, F von Minckwitz, G Mamounas, E Brennan, M Ciatto, S Houssami, N Br J Cancer Clinical Study BACKGROUND: Magnetic resonance imaging (MRI) has been proposed to guide breast cancer surgery by measuring residual tumour after neoadjuvant chemotherapy. This study-level meta-analysis examines MRI's agreement with pathology, compares MRI with alternative tests and investigates consistency between different measures of agreement. METHODS: A systematic literature search was undertaken. Mean differences (MDs) in tumour size between MRI or comparator tests and pathology were pooled by assuming a fixed effect. Limits of agreement (LOA) were estimated from a pooled variance by assuming equal variance of the differences across studies. RESULTS: Data were extracted from 19 studies (958 patients). The pooled MD between MRI and pathology from six studies was 0.1 cm (95% LOA: −4.2 to 4.4 cm). Similar overestimation for MRI (MD: 0.1 cm) and ultrasound (US) (MD: 0.1 cm) was observed, with comparable LOA (two studies). Overestimation was lower for MRI (MD: 0.1 cm) than mammography (MD: 0.4 cm; two studies). Overestimation by MRI (MD: 0.1 cm) was smaller than underestimation by clinical examination (MD: −0.3 cm). The LOA for mammography and clinical examination were wider than that for MRI. Percentage agreement between MRI and pathology was greater than that of comparator tests (six studies). The range of Pearson's/Spearman's correlations was wide (0.21–0.92; 16 studies). Inconsistencies between MDs, percentage agreement and correlations were common. CONCLUSION: Magnetic resonance imaging appears to slightly overestimate pathologic size, but measurement errors may be large enough to be clinically significant. Comparable performance by US was observed, but agreement with pathology was poorer for mammography and clinical examination. Percentage agreement can provide supplementary information to MDs and LOA, but Pearson's/Spearman's correlation does not provide evidence of agreement and should be avoided. Further comparisons of MRI and other tests using the recommended methods are warranted. Nature Publishing Group 2013-09-17 2013-08-20 /pmc/articles/PMC3776985/ /pubmed/23963140 http://dx.doi.org/10.1038/bjc.2013.473 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Marinovich, M L
Macaskill, P
Irwig, L
Sardanelli, F
von Minckwitz, G
Mamounas, E
Brennan, M
Ciatto, S
Houssami, N
Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
title Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
title_full Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
title_fullStr Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
title_full_unstemmed Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
title_short Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
title_sort meta-analysis of agreement between mri and pathologic breast tumour size after neoadjuvant chemotherapy
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776985/
https://www.ncbi.nlm.nih.gov/pubmed/23963140
http://dx.doi.org/10.1038/bjc.2013.473
work_keys_str_mv AT marinovichml metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT macaskillp metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT irwigl metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT sardanellif metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT vonminckwitzg metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT mamounase metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT brennanm metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT ciattos metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy
AT houssamin metaanalysisofagreementbetweenmriandpathologicbreasttumoursizeafterneoadjuvantchemotherapy